Gene Therapy for Sickle Cell Disease: Competitive Landscape, Clinical Development Programs

- Sickle cell disease is an inherited blood disorder of hemoglobin synthesis 
- Affects 100,000 individuals in the United States
- Financial forecast show approximately 1 billion dollar market with CGAR of 14.3%
- Potential curative gene therapy are being Bluebird Bio, Aruvant Therapeutics, CRISPR Therapeutics, Editas Therapeutics, Intellia Therapeutics, Sangamo Biosciences, Homology Medicine
- Bluebird Bio has a competitive advantage 

Learn More


Pages You May Like